

# Rogier W Sanders

## List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/3508551/publications.pdf](https://exaly.com/author-pdf/3508551/publications.pdf)

Version: 2025-02-01

186

PR articles

17,127

PR citations

8651

65

PR h-index

9871

126

g-index

200

documents

20458

doc citations

8143

72

h-index

18932

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines. <i>Npj Vaccines</i> , 2024, 9, .	5.4	8
2	CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits. <i>Nature Communications</i> , 2024, 15, .	13.9	6
3	Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. <i>Science Immunology</i> , 2024, 9, .	13.5	27
4	Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques. <i>Science Immunology</i> , 2024, 9, .	13.5	15
5	Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. <i>Journal of Experimental Medicine</i> , 2024, 221, .	9.4	14
6	Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes. <i>PLoS Pathogens</i> , 2024, 20, e1012558.	4.4	8
7	Signatures of VH1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteins. <i>Nature Communications</i> , 2023, 14, .	13.9	10
8	Assessing immunogenicity barriers of the HIV-1 envelope trimer. <i>Npj Vaccines</i> , 2023, 8, .	5.4	1
9	A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. <i>Cell Reports Medicine</i> , 2022, 3, 100486.	6.7	20
10	SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs. <i>European Journal of Immunology</i> , 2022, 52, 646-655.	3.2	15
11	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	6.7	10
12	Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115650.	1.7	4
13	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. <i>Journal of Virology</i> , 2022, 96, .	3.7	11
14	The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. <i>Journal of Virology</i> , 2022, 96, .	3.7	21
15	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. <i>Blood Advances</i> , 2022, 6, 1537-1546.	5.1	57
16	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, .	5.4	23
17	Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns. <i>PLoS Pathogens</i> , 2022, 18, e1010340.	4.4	21
18	Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. <i>Journal of Experimental Medicine</i> , 2022, 219, .	9.4	24

#	ARTICLE	IF	PR CITATIONS
19	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. <i>Scientific Reports</i> , 2022, 12, .	3.5	13
20	Computed tomography and [18F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates. <i>iScience</i> , 2022, 25, 104101.	3.6	10
21	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, .	5.4	5
22	Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1949-1957.	6.2	63
23	Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. <i>Cell Reports Medicine</i> , 2022, 3, 100635.	6.7	12
24	Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions. <i>Frontiers in Immunology</i> , 2022, 13, .	5.1	21
25	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003991.	8.5	96
26	B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. <i>Cell Reports</i> , 2022, 39, 111021.	6.4	14
27	A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. <i>Nature Communications</i> , 2022, 13, .	13.9	65
28	Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. <i>Nature Communications</i> , 2022, 13, .	13.9	16
29	Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, .	13.9	17
30	Structure of the hepatitis C virus E1E2 glycoprotein complex. <i>Science</i> , 2022, 378, 263-269.	36.4	76
31	Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates. <i>Npj Vaccines</i> , 2022, 7, .	5.4	13
32	Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate. <i>Nature Communications</i> , 2022, 13, .	13.9	40
33	Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. <i>Science</i> , 2021, 371, .	36.4	352
34	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. <i>Npj Vaccines</i> , 2021, 6, .	5.4	47
35	Virus vaccines: proteins prefer prolines. <i>Cell Host and Microbe</i> , 2021, 29, 327-333.	15.3	98
36	Production of HIV-1 Env-Specific Antibodies Mediating Innate Immune Functions Depends on Cognate Interleukin-21- Secreting CD4 <sup>+</sup> T Cells. <i>Journal of Virology</i> , 2021, 95, .	3.7	4

#	ARTICLE	IF	PR CITATIONS
37	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 1188-1200.e19.	34.1	194
38	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. <i>Science Advances</i> , 2021, 7, .	11.0	139
39	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. <i>Cell Reports</i> , 2021, 35, 108933.	6.4	58
40	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021, 29, 806-818.e6.	15.3	69
41	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	13.5	540
42	Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity. <i>Nutrients</i> , 2021, 13, 1645.	4.7	60
43	High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. <i>Science Translational Medicine</i> , 2021, 13, .	12.7	219
44	Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. <i>Pathogens and Immunity</i> , 2021, 6, 116-134.	1.6	123
45	Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. <i>Biochemistry</i> , 2021, 60, 2153-2169.	2.4	61
46	Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. <i>Vaccines</i> , 2021, 9, 750.	3.0	15
47	Influenza A Virus Hemagglutinin Trimer, Head and Stem Proteins Identify and Quantify Different Hemagglutinin-Specific B Cell Subsets in Humans. <i>Vaccines</i> , 2021, 9, 717.	3.0	21
48	Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2021, 6, .	5.4	20
49	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009736.	4.4	27
50	Intramolecular quality control: HIV-1 envelope gp160 signal-peptide cleavage as a functional folding checkpoint. <i>Cell Reports</i> , 2021, 36, 109646.	6.4	14
51	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. <i>Nature Communications</i> , 2021, 12, .	13.9	71
52	Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface. <i>Journal of Virology</i> , 2021, 95, .	3.7	3
53	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021, 7, .	11.0	105
54	Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. <i>EMBO Journal</i> , 2021, 40, .	7.4	82

#	ARTICLE	IF	PR CITATIONS
55	Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. <i>EBioMedicine</i> , 2021, 72, 103589.	9.9	21
56	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. <i>Nature Communications</i> , 2021, 12, .	13.9	50
57	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. <i>ACS Central Science</i> , 2021, 7, 1863-1873.	9.2	34
58	Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. <i>Journal of the International AIDS Society</i> , 2021, 24, .	3.6	40
59	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. <i>Npj Vaccines</i> , 2021, 6, .	5.4	15
60	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. <i>Journal of Virology</i> , 2020, 94, .	3.7	16
61	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. <i>Cell Reports</i> , 2020, 33, 108274.	6.4	172
62	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. <i>Immunity</i> , 2020, 53, 1272-1280.e5.	23.3	225
63	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. <i>PLoS Pathogens</i> , 2020, 16, e1008665.	4.4	67
64	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2020, 16, e1008753.	4.4	87
65	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020, 16, e1008817.	4.4	112
66	Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. <i>Vaccines</i> , 2020, 8, 440.	3.0	12
67	Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice. <i>MAbs</i> , 2020, 12, .	10.3	5
68	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020, 369, 643-650.	36.4	1,236
69	HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. <i>Science Advances</i> , 2020, 6, .	11.0	22
70	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. <i>Cell</i> , 2020, 180, 471-489.e22.	34.1	145
71	Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions. <i>Structure</i> , 2020, 28, 897-909.e6.	3.8	56
72	Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits. <i>Journal of Virology</i> , 2020, 94, .	3.7	76

#	ARTICLE	IF	PR CITATIONS
73	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. <i>Journal of Virology</i> , 2020, 94, .	3.7	31
74	Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. <i>Journal of Virology</i> , 2019, 93, .	3.7	13
75	Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. <i>PLoS Pathogens</i> , 2019, 15, e1007920.	4.4	77
76	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. <i>Nature Communications</i> , 2019, 10, .	13.9	199
77	HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry. <i>Journal of Biological Chemistry</i> , 2019, 294, 5736-5746.	2.2	36
78	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. <i>Nature Communications</i> , 2019, 10, .	13.9	146
79	Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2019, 25, 873-883.e5.	15.3	54
80	Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. <i>Viruses</i> , 2019, 11, 384.	3.3	8
81	Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2264-2277.	3.2	20
82	Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. <i>Journal of Biological Chemistry</i> , 2019, 294, 5616-5631.	2.2	22
83	Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide. <i>Nature Communications</i> , 2019, 10, .	13.9	38
84	Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 302-308.	3.3	33
85	The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, .	5.1	2
86	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019, 50, 241-252.e6.	23.3	179
87	Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. <i>Journal of Virology</i> , 2019, 93, .	3.7	74
88	Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. <i>Journal of Proteome Research</i> , 2018, 17, 987-999.	3.5	24
89	Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. <i>Journal of Virology</i> , 2018, 92, .	3.7	79
90	Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. <i>Journal of Biological Chemistry</i> , 2018, 293, 1688-1701.	2.2	42

#	ARTICLE	IF	PR CITATIONS
91	cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. <i>Biotechnology and Bioengineering</i> , 2018, 115, 885-899.	3.9	84
92	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018, 49, 1162-1174.e8.	23.3	69
93	Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. <i>Retrovirology</i> , 2018, 15, .	3.6	37
94	Harnessing post-translational modifications for next-generation HIV immunogens. <i>Biochemical Society Transactions</i> , 2018, 46, 691-698.	4.1	5
95	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. <i>PLoS Pathogens</i> , 2018, 14, e1006986.	4.4	29
96	Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability. <i>Frontiers in Immunology</i> , 2018, 9, .	5.1	56
97	Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 790-793.	1.5	11
98	Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. <i>PLoS Pathogens</i> , 2018, 14, e1006913.	4.4	134
99	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. <i>Science Translational Medicine</i> , 2017, 9, .	12.7	159
100	Native-like Env trimers as a platform for HIV-1 vaccine design. <i>Immunological Reviews</i> , 2017, 275, 161-182.	6.6	243
101	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017, 18, 2175-2188.	6.4	79
102	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017, 46, 1073-1088.e6.	23.3	335
103	Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. <i>Journal of Virology</i> , 2017, 91, .	3.7	60
104	Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. <i>Journal of Virology</i> , 2017, 91, .	3.7	35
105	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. <i>Cell Reports</i> , 2017, 20, 1805-1817.	6.4	195
106	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. <i>Journal of Experimental Medicine</i> , 2017, 214, 2573-2590.	9.4	196
107	High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. <i>Journal of Virology</i> , 2017, 91, .	3.7	25
108	The microanatomic segregation of selection by apoptosis in the germinal center. <i>Science</i> , 2017, 358, .	36.4	271

#	ARTICLE	IF	PR CITATIONS
109	Opposites attract in bispecific antibody engineering. <i>Journal of Biological Chemistry</i> , 2017, 292, 14718-14719.	2.2	3
110	A single mutation in Taiwanese H6N1 influenza hemagglutinin switches binding to human-type receptors. <i>EMBO Molecular Medicine</i> , 2017, 9, 1314-1325.	7.2	48
111	Three mutations switch H7N9 influenza to human-type receptor specificity. <i>PLoS Pathogens</i> , 2017, 13, e1006390.	4.4	108
112	HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. <i>PLoS ONE</i> , 2017, 12, e0181886.	2.4	17
113	The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1135-1142.	1.5	16
114	Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, .	7.6	392
115	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. <i>Cell Reports</i> , 2016, 16, 2327-2338.	6.4	258
116	Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. <i>Cell Reports</i> , 2016, 17, 2195-2209.	6.4	178
117	HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. <i>Retrovirology</i> , 2016, 13, .	3.6	25
118	Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. <i>Journal of Virology</i> , 2016, 90, 813-828.	3.7	35
119	Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. <i>Journal of Immunology</i> , 2016, 197, 994-1002.	0.6	145
120	HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. <i>Expert Review of Vaccines</i> , 2016, 15, 349-365.	4.1	49
121	HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. <i>Trends in Immunology</i> , 2016, 37, 221-232.	10.6	101
122	Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. <i>Cell Reports</i> , 2016, 14, 2695-2706.	6.4	281
123	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. <i>Nature Microbiology</i> , 2016, 2, .	16.5	167
124	Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. <i>PLoS Pathogens</i> , 2016, 12, e1005864.	4.4	150
125	Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer. <i>Biomolecules</i> , 2015, 5, 2919-2934.	4.4	15
126	Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-Na <sup>+</sup> -ve Chronically HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0120648.	2.4	6

#	ARTICLE	IF	PR CITATIONS
127	Colorectal Mucus Binds DC-SIGN and Inhibits HIV-1 Trans-Infection of CD4+ T-Lymphocytes. PLoS ONE, 2015, 10, e0122020.	2.4	12
128	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathogens, 2015, 11, e1005110.	4.4	89
129	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathogens, 2015, 11, e1005238.	4.4	53
130	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell, 2015, 163, 1702-1715.	34.1	383
131	Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Immunity, 2015, 43, 1053-1063.	23.3	209
132	Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell Reports, 2015, 11, 1604-1613.	6.4	148
133	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nature Communications, 2015, 6, .	13.9	145
134	HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 2015, 349, .	36.4	521
135	Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. AIDS Research and Human Retroviruses, 2015, 31, 1160-1165.	1.5	15
136	What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?. Journal of Virology, 2015, 89, 5981-5995.	3.7	27
137	Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer. PLoS Pathogens, 2015, 11, e1004767.	4.4	103
138	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell, 2015, 161, 1505-1515.	34.1	267
139	A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B <i>env</i> Gene. Journal of Virology, 2015, 89, 3380-3395.	3.7	266
140	Immunosilencing a Highly Immunogenic Protein Trimerization Domain. Journal of Biological Chemistry, 2015, 290, 7436-7442.	2.2	71
141	Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Acta Crystallographica Section D: Biological Crystallography, 2015, 71, 2099-2108.	3.1	76
142	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nature Communications, 2015, 6, .	13.9	98
143	Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. Journal of Virology, 2015, 89, 10383-10398.	3.7	174
144	Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody. Journal of Immunology, 2015, 195, 3759-3768.	0.6	4

#	ARTICLE	IF	PR CITATIONS
145	Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11947-11952.	7.6	135
146	Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. Journal of Virology, 2015, 89, 12189-12210.	3.7	92
147	Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology, 2015, 486, 116-120.	2.3	50
148	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17624-17629.	7.6	377
149	Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. Aids, 2014, 28, 1237-1240.	2.5	20
150	Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity, 2014, 40, 657-668.	23.3	366
151	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014, 509, 55-62.	38.7	737
152	Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers. Immunity, 2014, 40, 669-680.	23.3	341
153	ADSI-1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1296-1305.	2.2	29
154	Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology, 2014, 11, .	3.6	143
155	CD4-Induced Activation in a Soluble HIV-1 Env Trimer. Structure, 2014, 22, 974-984.	3.8	113
156	Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL. PLoS ONE, 2014, 9, e107683.	2.4	4
157	Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer. Science, 2013, 342, 1477-1483.	36.4	834
158	Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer. Science, 2013, 342, 1484-1490.	36.4	701
159	HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. Retrovirology, 2013, 10, .	3.6	39
160	Broadly neutralizing antibodies against HIV-1: Templates for a vaccine. Virology, 2013, 435, 46-56.	2.3	110
161	Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature Structural and Molecular Biology, 2013, 20, 796-803.	8.7	341
162	Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans. PLoS Pathogens, 2013, 9, e1003342.	4.4	286

#	ARTICLE	IF	PR CITATIONS
163	A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. <i>PLoS Pathogens</i> , 2013, 9, e1003618.	4.4	980
164	Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4351-4356.	7.6	244
165	How Can HIV-Type-1-Env Immunogenicity Be Improved to Facilitate Antibody-Based Vaccine Development?. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1-15.	1.5	71
166	A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield. <i>Science</i> , 2011, 334, 1097-1103.	36.4	679
167	Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. <i>Virology</i> , 2010, 401, 236-247.	2.3	71
168	Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion Inhibitors. <i>Journal of Biological Chemistry</i> , 2009, 284, 26941-26950.	2.2	73
169	Optimization of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins with V1/V2 Deleted, Using Virus Evolution. <i>Journal of Virology</i> , 2009, 83, 368-383.	3.7	43
170	Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. <i>Virology</i> , 2009, 389, 108-121.	2.3	50
171	The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. <i>Retrovirology</i> , 2008, 5, 10.	3.6	44
172	Only Five of 10 Strictly Conserved Disulfide Bonds Are Essential for Folding and Eight for Function of the HIV-1 Envelope Glycoprotein. <i>Molecular Biology of the Cell</i> , 2008, 19, 4298-4309.	2.5	46
173	Evolution Rescues Folding of Human Immunodeficiency Virus-1 Envelope Glycoprotein GP120 Lacking a Conserved Disulfide Bond. <i>Molecular Biology of the Cell</i> , 2008, 19, 4707-4716.	2.5	12
174	HIV-1 gp120 Mannoses Induce Immunosuppressive Responses from Dendritic Cells. <i>PLoS Pathogens</i> , 2007, 3, e169.	4.4	137
175	Protein Promiscuity: Drug Resistance and Native Functions—HIV-1 Case. <i>Journal of Biomolecular Structure and Dynamics</i> , 2005, 22, 615-624.	2.8	24
176	Evolutionary Repair of HIV Type 1 gp41 with a Kink in the N-Terminal Helix Leads to Restoration of the Six-Helix Bundle Structure. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 742-749.	1.5	21
177	Title is missing!. <i>Retrovirology</i> , 2004, 1, 3.	3.6	34
178	Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2002, 76, 8875-8889.	3.7	450
179	Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein. <i>Journal of Virology</i> , 2002, 76, 7760-7776.	3.7	152
180	Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. <i>Journal of Virology</i> , 2002, 76, 2606-2616.	3.7	143

#	ARTICLE	IF	PR CITATIONS
181	Differential Transmission of Human Immunodeficiency Virus Type 1 by Distinct Subsets of Effector Dendritic Cells. <i>Journal of Virology</i> , 2002, 76, 7812-7821.	3.7	145
182	A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure. <i>Journal of Virology</i> , 2000, 74, 627-643.	3.7	527
183	Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide. <i>ELife</i> , 0, 6, .	1.6	54
184	Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. <i>ELife</i> , 0, 9, .	1.6	166
185	Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. <i>ELife</i> , 0, 10, .	1.6	103
186	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. <i>ELife</i> , 0, 11, .	1.6	16